Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Inclusion Criteria:

* Histologically confirmed diagnosis of a gynecologic tumour \[(non-epithelial ovarian tumour without germcell-tumours, tumours of the uterus (eg. Muellerian mixed tumours, Endometrial carcinomas, Uterus sarcoma, Cancer of the cervix)\]
* Target or non-target lesion. Patients with epithelial ovarian carcinoma are qualified also if they have a CA 125 increase only.
* Patients with ovarian carcinoma must have completed a platin-containing chemotherapy more than 6 months at least. Patients with other malignancies could have prior chemotherapy, but must'nt
* Prior Radiotherapy less than 25% of haemapoietic system is allowed, but should have completed at least 6 weeks prior or registration
* Prior antitumoral hormone therapy, or specific immunotherapy is allowed, treatment have to be completed at least 3 weeks prior of registration
* All women with childbearing potential have to be a negative pregnancy test within 7 days of registration
* Perfomance Status 0-2 ECOG or more than 60% according to Karnofsky Index
* Estimated expectancy of life of more than 12 weeks
* adequate hematologic, renal and hepatic function according to following definitions: absolute Neutrophils \>= 1,5 n/L Platelets \>= 100 n/L Bilirubine \<= 1,25 x ULN estimated glomerular filtration rate (Jelliffe) \>= 60 ml/min
* Patients who have given their signed and written informed consent to participate in the trial
* Patients must be geographically accessible for treatment and follow

Exclusion Criteria:

* More than 2 prior chemotherapies (or Radio-Chemotherapies)
* active infection or concurrent severe medical problems unrelated to malignancy which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
* application of other cytotoxic or antitumoral agents during study period
* Patients with a history of seizure disorder or central nervous system disorders
* History of congestive heart failure (NYHA Classification \> 2, even if medically controlled.
* History of clinical and electrocardiographically documented myocardial infarction within the last 6 months.
* History of atrial or ventricular arrhythmias (\> LOWN II)
* Women who are pregnant or breast feeding
* Fertile women not using adequate contraceptive measures
* Patients who have used any investigational drugs within 30 days of study entry